AbCellera Biologics (ABCL) said Health Canada authorized its clinical trial application for a phase 1 study of an investigational antibody medicine designed for the non-hormonal treatment of moderate-to-severe vasomotor symptoms, known as hot flashes, associated with menopause.
The trial for ABCL635 is expected to begin in Q3 and will evaluate the treatment's safety profile, pharmacokinetics and pharmacodynamics in healthy participants and postmenopausal women with symptoms, the Vancouver-based company said Wednesday in a statement.
The company's shares rose 0.1% in after-hours trading.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.